title: Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al.
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Parker
authors.forename: Thomas
authors.initials: T
authors.lastname: Rennie
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004345:Drug Industry; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D016559:Tacrolimus